Physician profile
Michael Devito
NPI 1710963160
$304.47
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $146 · 2022: $41.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $187.36 | 2021-2022 | |
| Optinose US, INC. | $47.24 | 2019 | |
| Ethicon US, LLC | $21.20 | 2019 | |
| Acclarent, INC | $19.40 | 2019 | |
| Stryker Corporation | $17.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Devito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.